M Shankar Ganesh, N Venkateswaramurthy
Department of Pharmacy Practice, JKKN College of Pharmacy, The Tamil Nadu Dr. M.G.R. Medical University, India.
Curr Cancer Drug Targets. 2024 Oct 31. doi: 10.2174/0115680096329098240920043326.
Gastrointestinal (GI) cancers represent some of the most common and lethal malignancies globally, underscoring the urgent need for improved diagnostic strategies. Traditional diagnostic methods, while effective to some degree, are often invasive and unsuit-able for regular screenings.
This review article explores integrating machine learning (ML) with liquid biopsy techniques as a revolutionary approach to enhance the detection and monitoring of GI cancers. Liquid biopsies offer a non-invasive alternative for cancer detection through the analysis of circulating tumor DNA (ctDNA) and other biomarkers, which when combined with ML, can significantly improve diagnostic accuracy and patient outcomes.
We conducted a comprehensive review of recent advancements in liquid biopsy and ML, focusing on their synergistic potential in the early detection of GI cancers. The review addresses the application of next-generation sequencing and digital droplet PCR in enhancing the sensitivity and specificity of liquid biopsies.
Machine learning algorithms have demonstrated remarkable ability in navigating complex datasets and identifying diagnostically significant patterns in ctDNA and other circu-lating biomarkers. Innovations such as machine learning-enhanced "fragmentomics" and tomographic phase imaging flow cytometry illustrate significant strides in non-invasive cancer diagnostics, offering enhanced detection capabilities with high accuracy.
The integration of ML in liquid biopsy represents a transformative step in the early detection and personalized treatment of GI cancers. Future research should focus on overcoming current limitations, such as the heterogeneity of tumor-derived genetic materials and the standardization of liquid biopsy protocols, to fully realize the potential of this technol-ogy in clinical settings.
胃肠道(GI)癌是全球最常见且致命的恶性肿瘤之一,这凸显了改进诊断策略的迫切需求。传统诊断方法虽然在一定程度上有效,但通常具有侵入性,不适用于常规筛查。
本文综述探讨将机器学习(ML)与液体活检技术相结合,作为一种革命性方法来加强胃肠道癌的检测和监测。液体活检通过分析循环肿瘤DNA(ctDNA)和其他生物标志物,为癌症检测提供了一种非侵入性替代方法,与机器学习相结合时,可显著提高诊断准确性和患者治疗效果。
我们对液体活检和机器学习的最新进展进行了全面综述,重点关注它们在胃肠道癌早期检测中的协同潜力。该综述阐述了下一代测序和数字液滴PCR在提高液体活检的敏感性和特异性方面的应用。
机器学习算法在处理复杂数据集以及识别ctDNA和其他循环生物标志物中具有诊断意义的模式方面表现出卓越能力。诸如机器学习增强的“片段组学”和断层相成像流式细胞术等创新技术,在非侵入性癌症诊断方面取得了显著进展,具备高精度的增强检测能力。
机器学习与液体活检相结合,代表了胃肠道癌早期检测和个性化治疗方面的变革性进展。未来研究应聚焦于克服当前的局限性,如肿瘤源性遗传物质的异质性和液体活检方案的标准化,以充分实现该技术在临床环境中的潜力。